Project Grant R42AG063640
- Summary: VR-CARES Federal Project Grant Award Rendever, Inc. received a Small Business Technology Transfer (STTR) Phase I grant of $349,333 from the National Institute on Aging under the Aging Research program (CFDA 93.866), effective May 1, 2025 through April 30, 2027. The project, titled "VR-CARES: Feasibility of Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support," develops and tests a novel virtual reality (VR) platform designed to address critical challenges...
- Federal Grant Award Summary Rendever, Inc. received a $1.35M Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded September 22, 2025, with completion targeted for May 31, 2028. The award funds development and commercialization of RenderVer, a clinically validated virtual reality (VR) platform designed to address social isolation and mental health challenges among older adults. The VR solution enables seniors—particularly those with...
- Summary Massachusetts General Hospital received a $722,746 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded February 15, 2026, with completion targeted for January 31, 2031. The grant funds the COMA Family Program (COMA-F), a multi-site clinical trial designed to test the efficacy of a resilience-based intervention addressing emotional distress in caregivers of patients with severe acute brain injury (SABI) who are comatose or...
- VOCALE Digital Intervention Research and Development The University of Washington received a $505,948 Project Grant award from the National Institute on Aging (CFDA 93.866 – Aging Research) effective March 1, 2026, through February 28, 2031, to develop and evaluate VOCALE, a web-based digital intervention designed to reduce frailty and improve quality of life among independently living residents in continuing care retirement communities (CCRCs). The deliverables include execution of a Stage II...
- CONNECT-AD Study: Summary of Grant Products and Services The National Institute on Aging (NIA) awarded the University of California, Los Angeles a $534,287 Project Grant on September 30, 2025, under the Aging Research program (CFDA 93.866) to develop and deliver research products addressing care coordination challenges in Alzheimer's disease and related dementias. The primary deliverable is the creation of the first multisite electronic health record (EHR) communication database incorporating...
- Grant Award Summary Viewmind Inc. received a $495,731 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded on September 20, 2025, with completion scheduled for September 19, 2026. The award funds an evaluation of Viewmind's digital health and artificial intelligence platform designed to detect beta-amyloid and tau burden consistent with Alzheimer's disease in persons with mild cognitive impairment (MCI) using machine learning, virtual reality...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $2,373,964 will fund a 3-year study examining the use of telehealth to improve care for long-stay nursing home residents with Alzheimer's disease and related dementias (ADRD). The key objectives are to: 1) qualitatively assess how telehealth is used in nursing homes and barriers/facilitators to its adoption, 2) characterize telehealth and in-person care utilization patterns for this population...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded a $120,858 Project Grant to the University of Maryland, Baltimore effective September 1, 2025, through June 30, 2030, under the Aging Research program (CFDA 93.866). This research initiative, titled "Preserving Ability Through Virtual Exercise (PAVE): An Intervention to Increase the Physical Activity of Hospitalized Older Adults," delivers a feasibility and preliminary efficacy study examining the use of...
- Grant Summary: Activities4Care Digital Platform Plans4Care Inc. received a $490,262 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded on June 15, 2025, with completion targeted for May 31, 2026. The award funds development and testing of Activities4Care, a digital platform designed to address the critical unmet need for meaningful activities among the 6+ million individuals living with Alzheimer's disease and Alzheimer's disease-related...
- Federal Grant Award Summary Emory University received a $627,646 Project Grant from the National Institute on Aging (Aging Research Program, CFDA 93.866) awarded February 15, 2026, with completion scheduled for January 31, 2031. The grant funds a randomized controlled trial testing the efficacy of REPAIR SLEEP, a 5-week cognitive behavioral therapy for insomnia (CBT-I) intervention delivered via videoconferencing to dyads consisting of persons living with dementia and their caregivers. The study...
USING RENDEVER TO IMPROVE THE QUALITY OF LIFE OF OLDER ADULTS WITH COGNITIVE IMPAIRMENTS IN SENIOR LIVING COMMUNITIES AND THEIR FAMILY MEMBERS WHO LIVE AT A DISTANCE. - THE UNITED STATES IS EXPERIENCING A PUBLIC HEALTH CRISIS ON A MASSIVE SCALE DUE TO THE NUMBER OF PEOPLE WITH DEMENTIA, LACK OF CURES, AND CHALLENGES ASSOCIATED WITH CAREGIVING FOR THIS POPULATION.1,2 UNTIL CURES FOR THE DEMENTIAS ARE DISCOVERED, NEW TECHNOLOGIES AND INTERVENTIONS ARE IMPERATIVE THAT CAN REDUCE THE STRESS AND EMOTIONAL BURDEN OF ALZHEIMER'S DISEASE (AD) AND ALZHEIMER'S DISEASE-RELATED-DEMENTIAS (ADRD) FOR OLDER ADULTS AND THEIR FAMILY MEMBERS (NIA STRATEGIC PLAN). UNFORTUNATELY, COVID-19 HAS EXACERBATED CHALLENGES RELATED TO SOCIAL ISOLATION AND POOR MENTAL HEALTH IN SENIOR LIVING COMMUNITIES. THE VIRTUAL REALITY (VR) PROGRAM, RENDEVER, PROVIDES AN INNOVATIVE AND AFFORDABLE SOLUTION TO THESE CHALLENGES BY ENABLING OLDER ADULTS IN SENIOR LIVING COMMUNITIES TO MAINTAIN IMPORTANT FAMILY RELATIONSHIPS, ENGAGE FULLY WITH LIFE, AND RECONNECT WITH THEIR PAST, REGARDLESS OF PHYSICAL LOCATION, THROUGH ITS ADVANCED COMMUNICATION AND NETWORK CAPABILITIES. THERE IS NEUROLOGICAL, BEHAVIORAL, AND PHYSIOLOGICAL EVIDENCE THAT VIRTUAL ENVIRONMENTS ALLOW PEOPLE TO FEEL THE EMOTIONAL PRESENCE OF OTHERS IN WAYS THAT SURPASS THEIR LOCATION IN SPACE.3 UNFORTUNATELY, LITTLE RESEARCH HAS EXAMINED ITS IMPACT ON OLDER ADULTS' SOCIAL RELATIONSHIPS, PRIMARILY DUE OF A LACK OF NETWORKING AND COMMUNICATION CAPABILITIES OF OTHER VR PROGRAMS. PHASE I TESTED THE FEASIBILITY OF RENDEVER WITH RESIDENTS WITH MILD COGNITIVE IMPAIRMENTS (MCI) OR MILD TO MODERATE DEMENTIA AND THEIR FAMILY MEMBERS WHO LIVED AT A DISTANCE. OUR RESULTS SHOWED IT TO BE SAFE, EASY TO USE, HIGHLY SATISFYING, AND TRANSFORMATIVE FOR THE 21 RESIDENT- FAMILY MEMBER DYADS WHO USED IT. RESIDENTS WITH MCI AND DEMENTIA EQUALLY LOVED THE VR, WITH RESIDENTS WITH DEMENTIA REPORTING GREATER IMMERSION. THIS PHASE II PROJECT EXPANDS OUR TEST OF THE LIVESTREAMING AND NETWORK FEATURES OF RENDEVER WITH 192 RESIDENT-ADULT CHILD DYADS ACROSS 12 SENIOR LIVING COMMUNITIES IN CENTRAL CALIFORNIA AND BOSTON WITH AN EXPERIMENTAL DESIGN. OUR AIMS FOCUS ON THE IMPACT OF RENDEVER ON THE QUALITY OF LIFE OF RESIDENTS AND THEIR ADULT CHILDREN WHO LIVE AT A DISTANCE AND WHETHER THIS ASSOCIATION DEPENDS UPON RESIDENTS' LEVEL OF COGNITIVE IMPAIRMENT. WE ALSO FOCUS ON THE ADULT CHILDREN AND WHETHER PARTICIPATING IN RENDEVER WITH THEIR PARENT REDUCES CARE-GIVER GUILT. IF PHASE II IS SUCCESSFUL, RENDEVER WILL BE THE ONLY PRODUCT THAT ALLOWS RESIDENTS TO STILL TRAVEL, VIEW FAMILY PHOTOS AND VIDEOS, AND GO BACK IN TIME TO ONE'S CHILDHOOD HOME AND OTHER MEMORABLE LOCATIONS WITH ONE'S FAMILY IN VR AND SHARE STORIES WHILE DOING IT, DESPITE GEOGRAPHICAL SEPARATION AND COGNITIVE/PHYSICAL CHALLENGES. IMPORTANTLY, PHASE II WILL PROVIDE A RIGOROUS, SCIENTIFIC TEST OF WHETHER RENDEVER CAN IMPROVE RESIDENTS' AND FAMILY MEMBERS' QUALITY OF LIFE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 3/28/25 | ||
| Not listed | $0 | 3/12/25 | ||
| Not listed | $0 | 3/12/25 | ||
| Not listed | $216.9k | 12/20/22 | ||
| Not listed | $216.9k | 12/20/22 |